Next report date
Report period
H1 2024
EPS estimate
—
Revenue estimate
—
−0.24HKD
−232.70 MHKD
241.74 MHKD
427.77 M
About ALPHAMAB ONCOLOGY
Sector
Industry
CEO
Ting Xu
Website
Headquarters
Suzhou
Employees (FY)
435
Founded
2008
FIGI
BBG00QX1PZW3
Alphamab Oncology is an investment holding company. It engages in the research and development, manufacturing and commercialization of biologics of oncology through its subsidiaries. The company was founded by Xu Ting in Novemeber 2008 and is headquartered in Suzhou, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 9966 is 4.67 HKD — it has increased by 4.94% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange ALPHAMAB ONCOLOGY stocks are traded under the ticker 9966.
ALPHAMAB ONCOLOGY is going to release the next earnings report on Aug 29, 2024. Keep track of upcoming events with our Earnings Calendar.
9966 stock is 5.17% volatile and has beta coefficient of 1.53. Check out the list of the most volatile stocks — is ALPHAMAB ONCOLOGY there?
9966 earnings for the last quarter are −0.18 HKD per share, whereas the estimation was −0.53 HKD resulting in a 65.34% surprise. The estimated earnings for the next quarter are −0.27 HKD per share. See more details about ALPHAMAB ONCOLOGY earnings.
ALPHAMAB ONCOLOGY revenue for the last quarter amounts to 179.19 M HKD despite the estimated figure of 183.72 M HKD. In the next quarter revenue is expected to reach 107.66 M HKD.
Yes, you can track ALPHAMAB ONCOLOGY financials in yearly and quarterly reports right on TradingView.
9966 stock has risen by 9.88% compared to the previous week, the month change is a 0.21% fall, over the last year ALPHAMAB ONCOLOGY has showed a 70.03% decrease.
9966 net income for the last quarter is −184.45 M HKD, while the quarter before that showed −45.08 M HKD of net income which accounts for −309.14% change. Track more ALPHAMAB ONCOLOGY financial stats to get the full picture.
Today ALPHAMAB ONCOLOGY has the market capitalization of 4.51 B, it has decreased by 2.11% over the last week.
No, 9966 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 9966 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALPHAMAB ONCOLOGY stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 435.00 employees. See our rating of the largest employees — is ALPHAMAB ONCOLOGY on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ALPHAMAB ONCOLOGY technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ALPHAMAB ONCOLOGY stock shows the sell signal. See more of ALPHAMAB ONCOLOGY technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ALPHAMAB ONCOLOGY future price: according to them, 9966 price has a max estimate of 5.28 HKD and a min estimate of 3.60 HKD. Read a more detailed ALPHAMAB ONCOLOGY forecast: see what analysts think of ALPHAMAB ONCOLOGY and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ALPHAMAB ONCOLOGY EBITDA is −279.30 M HKD, and current EBITDA margin is −116.20%. See more stats in ALPHAMAB ONCOLOGY financial statements.